Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

1.

Unicentric Castleman disease, hyaline vascular variant, stromal rich, with increased plasma cells and a high level of serum IL-6: Raising the diagnostic and therapeutic issues.

Lyapichev KA, Sukswai N, Strati P, Iyer SP, Medeiros LJ, Miranda RN.

Ann Diagn Pathol. 2019 Aug 3;43:151398. doi: 10.1016/j.anndiagpath.2019.08.002. [Epub ahead of print] No abstract available.

PMID:
31630065
2.

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.

Strati P, Ahmed MAA, Fowler N, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS.

Haematologica. 2019 Oct 10. pii: haematol.2019.230649. doi: 10.3324/haematol.2019.230649. [Epub ahead of print]

3.

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.

Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG.

Blood. 2019 Nov 28;134(22):1951-1959. doi: 10.1182/blood.2019001077.

PMID:
31537528
4.

Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function.

Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Ju Lee H, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC.

Leuk Lymphoma. 2019 Aug 2:1-5. doi: 10.1080/10428194.2019.1644333. [Epub ahead of print] No abstract available.

PMID:
31373240
5.

The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.

Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG.

Br J Haematol. 2019 Oct;187(1):e1-e4. doi: 10.1111/bjh.16117. Epub 2019 Jul 25. No abstract available.

PMID:
31344256
6.

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12.

Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L.

Cancers (Basel). 2019 Jun 26;11(7). pii: E896. doi: 10.3390/cancers11070896.

7.

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection.

Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS.

Blood. 2019 Jun 27;133(26):2800-2802. doi: 10.1182/blood.2019000888. Epub 2019 May 17. No abstract available.

PMID:
31101626
8.

Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis.

Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A.

Ann Hematol. 2019 Jul;98(7):1611-1616. doi: 10.1007/s00277-019-03708-9. Epub 2019 May 15.

PMID:
31093708
9.

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A.

Blood Adv. 2019 May 14;3(9):1533-1539. doi: 10.1182/bloodadvances.2019031336.

10.

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.

Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ.

Haematologica. 2019 May 9. pii: haematol.2019.220012. doi: 10.3324/haematol.2019.220012. [Epub ahead of print]

11.

Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach.

Strati P, Ferrajoli A.

Drugs Aging. 2019 Sep;36(9):841-851. doi: 10.1007/s40266-019-00678-5. Review.

PMID:
31055788
12.

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.

Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F.

Am J Hematol. 2019 Jul;94(7):E188-E190. doi: 10.1002/ajh.25490. Epub 2019 Apr 29. No abstract available.

PMID:
30977182
13.

Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.

Strati P, Neelapu SS.

Curr Oncol Rep. 2019 Mar 27;21(5):38. doi: 10.1007/s11912-019-0789-z. Review.

PMID:
30919158
14.

Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma.

Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS.

Am J Hematol. 2019 Jun;94(6):E150-E153. doi: 10.1002/ajh.25447. Epub 2019 Mar 6. No abstract available.

PMID:
30785215
15.

A Rare Case of Triple-Negative Essential Thrombocythemia in a Young Postsplenectomy Patient: A Diagnostic Challenge.

Akcan T, Strati P, Yan M, Idowu M.

Case Rep Hematol. 2018 Dec 16;2018:9079462. doi: 10.1155/2018/9079462. eCollection 2018.

16.

Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma.

Strati P, Patel S, Nastoupil L, Fanale MA, Bollard CM, Lin AY, Gordon LI.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:592-603. doi: 10.1200/EDBK_200549. Review.

17.

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ.

Haematologica. 2019 Feb;104(2):e65-e67. doi: 10.3324/haematol.2018.199844. Epub 2018 Sep 6. No abstract available.

18.

Renal complications of primary myelofibrosis.

Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A.

Leuk Lymphoma. 2019 Feb;60(2):507-510. doi: 10.1080/10428194.2018.1474525. Epub 2018 Jul 3. No abstract available.

PMID:
29966471
19.

Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia.

Strati P, Gabutti C, Thompson PA, Kontoyiannis DP, Ferrajoli A.

Leuk Lymphoma. 2019 Feb;60(2):535-537. doi: 10.1080/10428194.2018.1474527. Epub 2018 Jun 18. No abstract available.

PMID:
29911929
20.

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.

Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG.

Leukemia. 2018 Nov;32(11):2388-2398. doi: 10.1038/s41375-018-0132-y. Epub 2018 Apr 17.

Supplemental Content

Loading ...
Support Center